Introduction
One of the major obstacles to the effective treatment of cancer with conventional chemotherapies is the development of multidrug resistance (MDR) by the tumor cells. P-glycoprotein (Pgp) encoded by MDR1 gene, a 170 kD transporter situated in the plasma membrane, has been shown to be responsible for cancer resistance to multiple chemotherapeutic agents. [1] [2] [3] [4] Pgp uses energy from ATP hydrolysis to export a diverse range of substrates including a variety of anticancer drugs. [1] [2] [3] [4] Increased level of Pgp expression could be induced by anticancer drug treatment, but also has been found in many types of tumors that had not been exposed to chemotherapies. 5 The level of Pgp expression has been established to be a useful factor in predicting both the rate of tumor response to a particular treatment regimen and the rate of relapse after the therapy. 6, 7 Further, in patients with solid tumors such as carcinomas of colon and liver, high-level Pgp expression was observed on the invasive edge of primary tumors, in lymph nodes and other metastatic lesions, suggesting that Pgp may play an important role in the cascade of molecular events associated with tumor progression including invasion and metastasis. 8, 9 Taken together, these observations suggest that Pgp may represent not only a good prognostic factor but also a potential therapeutic target for cancer intervention, especially for metastatic and relapsed diseases. A number of experimental compounds, including verapamil and trifluoperazine, have been studied with various efficacies in reversing MDR phenotype in cancer cells. 10 The application of these compounds is, however, very limited due to their unfavorable toxicity profiles.
Owing to its exclusive specificity, monoclonal antibody (mAb) may represent a promising class of agents for targeting drug-resistant cancer cells. In the past years, a number of mAb directed against Pgp have been produced. 11 Some of these mAb have been utilized as reagents for detecting and quantifying Pgp expression in both laboratory cell lines and clinical tumor specimens; whereas others have been used as potential therapeutic agents, either by directly reversing the MDR phenotype [12] [13] [14] [15] or by serving as a targeting device to deliver other cytotoxic moieties to kill the Pgp-expressing cancer cells. 16, 17 In this regard, immunotherapy with an antiPgp Â anti-effector cell bispecific antibody (BsAb) may provide a valuable alternative approach to treating MDR cancers. BsAb can bind simultaneously to tumor-associated antigens (eg Pgp) on tumor cell surface and triggering molecules on the effector cells, leading to effector cell activation and subsequent tumor killing. 18, 19 Several markers on effector cell surface, such as CD2 and CD3 on T cells, CD16 on natural killer cells, CD64 on macrophages and granulocytes, have been used for effector cell targeting and activation. 18, 19 A number of BsAb have demonstrated potent antitumor efficacy both in vitro and in animal models as well as in several small-scale clinic trials. 20, 21 We previously constructed single chain Fv (scFv) fragments of an anti-CD3mAb and an anti-Pgp mAb using antibody variable genes cloned from the respective hybridoma cell lines and demonstrated that both scFv fragments could be produced in Escherichia coli in soluble forms with good retention of antigen-binding activities. 22, 23 In this study, we generated a bispecific anti-Pgp Â anti-CD3 diabody, and expressed the diabody in E. coli with high yield. The diabody was capable of binding to both Pgp-overexpressing tumor cells and CD3-positive human T cells with affinities comparable to those of parent scFv fragments. In the presence of activated human peripheral blood lymphocytes (PBL), the diabody mediated potent lysis of Pgp-overexpressing tumor cells, and effectively inhibited the growth of MDR human tumor xenografts in mouse models.
Materials and methods

Cell lines
Hybridoma cell lines secreting the anti-CD3 antibody HIT3a (IgG 2a , k) and the anti-Pgp antibody PHMA02 (IgG 1 , k) were established at the Institute of Hematology, Chinese Academy of Medical Sciences (Tianjin, China) as described previously. 24, 25 PHMA02 binds to extracellular epitope(s) on Pgp, but does not interfere with the efflux function of the protein. 25 The human chronic myelogenous leukemia cell line, K562, its MDR variant established in our laboratory, K562/A02 (Yang et al 26 ), the human epidermoid carcinoma line KB and its MDR counterpart KBv 200 (Zhang et al 27 ) , and the human acute T-cell leukemia line, Jurkat, were maintained in RPMI-1640 (Gibco-BRL, Beijing, China) supplemented with 10% fetal calf serum at 371C, 5% CO 2 .
Construction of the anti-Pgp Â anti-CD3 diabody Plasmids pAYZCD3 and pET28a( þ ) scFvPgp, encoding the anti-CD3 scFv and the anti-Pgp scFv, respectively, were used for the assembly of the expression plasmid for the bispecific diabody, pYZDCP (Figure 1 ), following a procedure described previously. 28 Briefly, two crossover scFv, pLH-T3a-Pgp and pLH-Pgp-T3a, were first constructed by annealing of PCR fragments of the anti-CD3 variable light chain (V L ) and the anti-Pgp variable heavy chain (V H ) and the anti-Pgp V L and the anti-CD3 V H , via a five-amino-acid linker, GlyGlyGlyGlySer. The expression plasmid for the cosecretion of the two crossover scFv was constructed by ligation of the SfiI/NheI and NheI/NotI fragments from pLH-T3a-Pgp and pLH-Pgp-T3a, respectively, into the expression vector pCANTAB 5E (Amersham Bioscience, Piscataway, NJ, USA). The constructs encoding the crossover scFv fragments were verified by the DNA sequencing.
Expression and purification of the anti-Pgp Â anti-CD3 diabody
Both the scFv and the diabody were secreted from E. coli. strain HB2151 containing the appropriate expression plasmid, grown at 301C in a shaker flask following a procedure described previously. 29 A periplasmic extract of the cells was prepared by resuspending the cell pellet in 25 mM Tris (pH 7.5) containing 20% (w/v) sucrose, 200 mM NaCl, and 1 mM EDTA, followed by incubation at 41C with gentle shaking for 1 h. After centrifugation at 15 000 rpm for 15 min, the soluble antibodies were purified from the supernatant by an anti-E tag affinity chromatography using the RPAS Purification Module (Amersham Bioscience). The endotoxin level of the purified antibody preparations was assayed routinely before their use in any in vitro and in vivo studies.
SDS-PAGE and size-exclusion chromatography analysis of the diabody
The anti-Pgp Â anti-CD3 diabody were electrophoresed in a 15% polyacrylamide gel (Novex, San Diego, CA, USA) under reducing conditions and stained with colloidal blue stain kit (Novex). The composition of the diabody was assessed by sizeexclusion FPLC on a Superdex 75 (9/60) column (Amersham Bioscience) using phosphate-buffered saline (PBS) (pH 7.4) at a flow rate of 0.25 ml/min. The retention time of the diabody was compared to a set of standard proteins, including bovine albumin (66 kD), egg albumin (45 kD), and chymotrypsinogen A (25 kD) (Sigma, St Louis, MO, USA) assayed under an identical condition.
Flow cytometry analysis of the diabody for binding to both T cells and Pgp-expressing tumor cells
Five cell lines, the human chronic myelogenous leukemia cell line K562 and its Pgp-overexpressing counterpart K562/A02, the human epidermoid carcinoma line KB and its MDR counterpart KBv 200 , and the human acute T-cell leukemia line Jurkat, were used for flow cytometry. Briefly, 1 Â 10 6 cells in 100 ml PBS were incubated with various antibodies (20 mg/ml) for 1 h at 41C. After washing three times with cold PBS, the cells were incubated with 100 ml anti-E-tag antibody (Amersham Bioscience) at 10 mg/ ml for 1 h, followed by incubation with 20 ml of FITC-labeled rabbit anti-mouse antibody (Institute of Hematology) for additional 30 min. The cells were washed and analyzed with a FACS flow cytometry (FACSCalibur, Becton Dickinson, San Jose, USA).
Affinity determination
The binding affinities of PHMA02 IgG, HT3a IgG, their scFv and the anti-Pgp Â anti-CD3 diabody to their target antigens were determined by a cell-based radioimmunoassay. Antibody (50 mg) was first labeled with 0.5 mCi of [ 125 I]iodide (Amersham Biosciences) following a protocol described previously. 30 The assay was performed in 15 ml polypropylene centrifuge tubes preblocked with PBS containing 0.2% (w/v) gelatin at 41C overnight. Briefly, 1 Â 10 6 K562/A02 or Jurkat cells were incubated in triplicate with increasing amounts of the radiolabeled antibody preparations for 1 h at room temperature, and the radioactivity in individual tubes was measured after 
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Preparation and stimulation of the effector cells
Human PBL were prepared and activated according to a procedure described previously. 32 Briefly, PBL were first obtained from heparinized blood of healthy volunteers by Ficoll-Hypaque (Institute of Hematology) density-gradient centrifugation and depleted of monocytes by adherence to plastic. For cell activation, the nonadherent cells were incubated in complete RPMI medium (10% FCS) containing 50 IU/ml of IL-2 (Boehringer Mannheim, Indianapolis, IN, USA) and 1 mg/ml of HIT3a for 72 h.
Cytotoxicity assay
Cr-release assay was performed to assess the efficacy of the diabody in mediating T-cell cytotoxicity. 33 The Pgpoverexpressing K562/A02 and KBv 200 cells, and their parent cells, K562 and KB cells, were used as the target cells. Briefly, 4 Â 10 6 target cells were first labeled with 200 mCi Na 2
51
CrO 4 (Perkin-Elmer Life Science, Inc., Boston, MA, USA) for 1 h at 371C. After three washes to remove free radioactivity, the labeled cells were dispensed in triplicate into microtiter plates containing various numbers of preactivated PBL in 100 ml medium. Antibodies (50 ml) were then added to the wells to start the assay. After incubation at 371C for 4 h, the supernatant was harvested and counted for radioactivity using a gamma counter. Maximum release was determined by incubating the target cells in 10% SDS and spontaneous release was determined by incubating the cells in medium alone. The percentages of cell lysis were calculated as following: percent of specific cell lysis ¼ (experimental releaseÀspontaneous release)C(maximal releaseÀspontaneous release) Â 100%.
Tissue distribution and tumor localization in mice bearing MDR human xenografts
Female BALB/C nude mice (Cancer Institute, Chinese Academy of Medical Sciences, Beijing, China), 4 to 6 weeks of age, were given total body irradiation (400 rad) 3 days prior to inoculation with 2 Â 10 7 of K562/A02 or K562 cells in the hind flank via subcutaneous injection. Diabody was radiolabeled with 125 I to a specific activity of 4.14 mCi/mg protein. On day 5 post-tumor inoculation when the xenografts reached the size of B90 mm 3 , each mouse was given 10 mg 125 I-labeled diabody intravenously via the tail veil. The mice were given potassium iodide in drinking water (0.04%) to protect the thyroid 48 h prior to administering the 125 I-diabody. A group of three mice were killed at predefined intervals, and the xenografted tumors, along with mouse tissues/organs, including blood, heart, liver, lung, spleen, and kidney, were collected, weighted, and counted for radioactivity using a gamma counter. The percent of injected dose that localized in per gram (ID%/g) tissues was then calculated. The tumor/nontumor (T/NT) localization ratios were calculated as: ID%/g tissue in tumorCID%/g tissue in normal organ.
Inhibition of growth of MDR human xenografts in vivo
Female BALB/C nude mice, 4 to 6 weeks of age, were given total body irradiation (400 rad) 3 days prior to inoculation with 2 Â 10 7 of the drug-resistant K562/A02, KBv 200 , or their parent K562 or KB cells in the hind flank via subcutaneous injection. Treatment was started 5 days post-tumor inoculation when the solid tumors reached the sizes of 80-100 mm 3 . Each mouse was given by intravenous injections via the tail veil PBS (control), diabody (50 mg/mouse), preactivated PBL (5 Â 10 6 cells/mouse), doxorubicin (4 mg/kg, Pharmacia & Upjohn SPA, Milan, Italy), a combination of HIT3a scFv (50 mg/mouse) and PHMA02 scFv (50 mg/mouse) and PBL (5 Â 10 6 cells/mouse), or a combination of diabody (50 mg/mouse) and PBL (5 Â 10 6 cells/mouse), every 7 days for a total of three doses. The tumors were measured three times a week and the tumor volume was calculated as:
, where l represents the longest axis of tumors (in mm) and w represents the axis perpendicular to l (in mm). The statistic analysis on tumor volumes between the control and the treatment groups was evaluated by the Student's test using a software, SAS system 6.12 (SAS Inc., Cary, NC, USA). At the end of the study, representative xenografts from the diabody/PBLtreated groups were excised, single cell suspensions were prepared and stained with PHMA02 for Pgp expression.
Results
Construction and production of the diabody
ScFv fragments derived from the hybridoma HIT3a and PHMA02 were used for generating the bispecific antiPgp Â anti-CD3 diabody. In constructing the diabody, the Cterminus of the anti-CD3 V L domain was first connected to the N-terminus of the anti-Pgp V H domain using a five-amino-acid linker, GlyGlyGlyGlySer, to restrict intrachain pairing of V L and V H . A second crossover scFv was similarly constructed by connecting the C-terminus of the anti-Pgp V L domain to the Nterminus of the anti-CD3 V H domain using the same linker. The crossover scFvs were then amplified by PCR and subcloned into an single vector for the expression of the diabody (Figure 1a) . A polypeptide tag, the E tag, was fused immediately to the Cterminus of the second crossover scFv for purification and detection purposes. The diabody was secreted from E. coli strain HB2151 containing the expression vector and grown in shake flasks. The soluble diabody was released from the periplasmic space of E. coli by osmotic shock and purified with an anti-E tag affinity chromatography. The yield of purified diabody in the shaker flask was B4-5 mg/l media from an overnight culture.
SDS-PAGE and size-exclusion analysis of the diabody
The purified scFv and diabody were analyzed by SDS-PAGE under reducing conditions (Figure 1b) . Both the anti-Pgp scFv and the anti-CD3 scFv yielded a single protein band of expected size, whereas the diabody was resolved into two protein bands under the electrophoretic conditions, which are in consistent with the calculated molecular weights of 28.3 and 26.1 kD, for the pLH-Pgp-T3a and the pLH-T3a-Pgp polypeptide chains, respectively. The solution behavior of the diabody was analyzed by a sizeexclusion FPLC. The retention times of the major peak (495%) of the diabody and the anti-Pgp scFv were 77.3 and 90.1 min, respectively (not shown
Dual specificity and affinity of the diabody
Flow cytometry was performed to confirm the dual specificities of the anti-Pgp Â anti-CD3 diabody. The diabody reacted with both the CD3-expressing human Jurkat T cells (Figure 2a) , and the Pgp-overexpressing cells, including K562/A02 (Figure 2b ) and KBv 200 (Figure 2d ), whereas the HIT3a scFv only bound to Jurkat cells (Figure 2a ) and PHMA02 scFv only bound to K562/ 02 (Figure 2b ) and KBv 200 (Figure 2d) . None of the antibodies showed significant binding to the parent K562 and KB cells that express Pgp at only a basal level (Figure 2c and e) .
The antigen-binding affinities of various antibodies and their fragments were determined by a cell-based radioimmunoassay followed by the Scatchard analysis ( Table 1 ). The diabody showed excellent binding affinities to both of its target cells: 50 nM to K562/A02 and 15 nM to T cells, respectively. In comparison, the anti-Pgp scFv had an affinity of 40 nM to K562/ A02 cells, whereas the anti-CD3 scFv had an affinity of 32 nM to T cells. As expected, owing to their bivalency binding capacity, the intact anti-Pgp antibody, PHMA02, and the intact anti-CD3 antibody, HIT3a, showed much higher affinities than their respective monovalent scFv (Table 1) . 
Specific cytotoxicity to Pgp-overexpressing tumor cells mediated by the diabody
Specific localization in Pgp-overexpressing xenografts by the diabody
In vivo localization of the diabody was investigated in mice bearing either the Pgp-overexpressing K562/A02 or the parent K562 xenografts. Consistent with previous observations with other small-size antibody fragments, most of the radioactivity appeared in the blood and kidneys within the first few hours (1-6 h) after administration to mice bearing either K562/A02 or K562 xenografts. The amounts of diabody localized in K562/ A02 xenografts (ID%/g tissue) surpassed those in most normal organs at 6 h postinjection and were approaching those in the blood and kidneys (Figure 5a ). It is pertinent to note that the diabody was cleared at a much slower rate from the xenografts than from the normal organs (Figure 5a ), and at 12 h postinjection the T/NT tissue localization ratio reached 2.7 and 3.8 for the blood and the kidneys, respectively (Figure 5b) . At 24 h, the T/NT ratios were 8.1 (blood), 18.8 (kidneys), 21.2 (lung), 32.3 (spleen), 39.7 (liver), and 62.4 (heart), indicating a highly selective localization in the xenografts by the diabody. In contrast, the diabody failed to show any preferential localization in K562 xenografts expressing only basal level of Pgp (Figure 5c and d). For example, at 24 h after administration, the T/NT ratios only reached 0.26, 0.87, 0.78, 1.04, 4.5, and 2.0, for blood, kidneys, lung, spleen, liver, and heart, respectively, which is B10-to 30-fold lower than those observed in K562/A02 xenografts.
Inhibition of Pgp-overexpressing xenograft growth in mice by the diabody
In these studies, nude mice bearing the Pgp-overexpressing K562/A02 or KBv 200 , or the parent K562 or KB xenografts were The bispecific diabody localizes selectively in Pgpoverexpressing K562/A02 xenografts in mice. K562/A02 or K562 tumor-bearing mice were injected intravenously with 125 I-labeled diabody and killed at predefined intervals. The xenografts, along with normal mouse organs, were collected, weighted, and counted for radioactivity localized in the tissues. 
of an HIT3a scFv and PHMA02 scFv and PBL, a combination of the diabody and PBL, or a chemotherapeutic agent, doxorubicin. The diabody, in combination with PBL, resulted in significant inhibition of both K562/A02 and KBv 200 tumors (Figure 6a and c) , but had no effect on the growth of K562 and KB tumors (Figure 6b and d) . Both the K562/A02 and KBv 200 xenografts resumed their growth at a rate similar to that of the control group 1 week after the last of the total of three treatments (Figure 6a and c) . In contrast, doxorubicin significantly inhibited the growth of K562 and KB tumors, but showed no effect on the growth of the drug-resistant K562/A02 and only marginal activity on KBv 200 tumors (Figure 6a and c) . As controls, diabody or PBL alone, or a combination of PBL and HIT3a scFv and PHMA02 scFv, did not demonstrate any antitumor activity in any xenograft models (Figure 6a-d) . It is pertinent to note that the combination of the diabody and PBL did not cause any overt toxicity to mice as monitored by body weight, whereas doxorubicin treatment resulted in B15% body weight loss in mice in all four models (not shown).
Tumor cells were recovered from the diabody plus PBLtreated KBv 200 and KB xenografts at the end of the study and examined for Pgp expression. As shown in Figure 7 , KBv 200 cells recovered from the xenografts retained the same Pgp expression level as those cells cultured in vitro (Figure 7a and b) . Similarly, xenotransplantation of KB cells did not significantly affect the expression of Pgp (Figure 7c and d) .
Discussion
Here, we constructed a bispecific diabody directed against both CD3 on T-lymphocyte surface and Pgp, a molecule responsible for cancer cell resistance to multiple chemotherapeutic agents. Consistent with previous reports with the chemically constructed anti-Pgp (MRK16) Â anti-CD3 (OKT3) BsAb, 34, 35 our diabody mediated strong lysis of Pgp-overexpressing tumor cells, but was much less potent in killing of cells with basal level Pgp expression. Further, here we demonstrated that the diabody localized selectively in Pgp-overexpressing xenografts, and when combined with activated PBL, induced significant inhibition in mice of xenografted tumors, including both a hematological tumor and a solid tumor, that were resistant to conventional chemotherapy. To our knowledge, this is the first report on the production of a recombinant anti-Pgp BsAb and the demonstration of such an antibody could effectively inhibit Pgp-overexpressing tumors both in vitro and in vivo in a specific manner.
It is well established that Pgp overexpression in cancer cells correlates directly to the level of MDR in vitro in various tumor a b c d Figure 6 The bispecific diabody, in combination with human PBL, efficiently inhibits the growth of Pgp-overexpressing human xenografts in mice. Each nude mouse was injected subcutaneously of 2 Â Further, overexpression of Pgp has been associated with increased tumor invasion and metastasis, as well as reduced survival in patients with a number of malignant tumors. [6] [7] [8] [9] Taken together, these observations suggest that Pgp may constitute an ideal target for anticancer intervention. Several approaches have been attempted to overcome Pgp-mediated MDR in cancer cells, including development of either novel cytotoxic agents that are not substrates of Pgp or modified analogs of the MDR drugs with no crossresistance, and use of sensitizers that interfere with the efflux function of Pgp, thereby restoring drug sensitivity in MDR cancer cells. Since Pgp overexpression is one of the major contributing factors in tumor escaping and also relapse after initial chemotherapies, direct killing and eradication of Pgp-overexpressing cancer cells may, therefore, provide an excellent strategy to enhance the therapeutic effects of the conventional anticancer agents. In this regard, mAb, owing to its selectivity towards a defined target, represents an attractive class of agents for targeting Pgpoverexpressing MDR cancer cells. A number of mAb directed against Pgp have been described in the past years with various properties and applications. While some of these mAb demonstrated their utilities as good diagnostic reagents for Pgp expression, others were shown to be able to inhibit Pgp functions to various degrees. For example, MRK16 and MRK17 were shown to modulate Pgp activity and to inhibit the growth of Pgp-overexpressing MDR cancer cells both in vitro and in vivo. [12] [13] [14] Another mAb, UIC2, was able to potentiate the cytotoxicity of MDR drugs by inhibiting Pgp efflux function. 15 In addition, anti-Pgp mAb have also been used as carriers for other cytotoxic agents for tumor-targeted delivery, for example, an MRK-16-Pseudomonas exotoxin (PE) immunotoxin 16 and an scFv 9F11-PE38 immunotoxin 17 were selectively cytotoxic to Pgp-overexpressing MDR tumor cells. One of the concerns with the anti-Pgp mAb-based therapies, either as a functional blocker or as a carrier for cytotoxic payload, is the broad and constitutive expression profile of Pgp in normal human tissues, including the liver, kidney, gastrointestinal track, lymphocytes, and blood-brain barrier, 1-4 -universal blockade of the function of Pgp and/or killing of Pgp-positive cells thus may result in significant nonspecific toxicity. For example, a single anti-Pgp immunotoxin molecule is sufficient to kill a cell upon entry into cytosol, and the 'by-stander' effects of an anti-Pgp mAb-based drug or radioisotope conjugate may cause significant damage to tissues or cells surrounding the Pgp-positive cells. In this regard, the anti-Pgp Â anti-CD3 bispecific diabody described in the present study may offer several efficacy and safety advantages over other forms of anti-Pgp mAb-based therapies. First, neither the anti-Pgp antibody (PHMA02) nor the diabody by itself affects the function of Pgp upon binding (our unpublished observations). In addition, the diabody, lacking the Fc domain, would not elicit other effector mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) and complement-mediated cytotoxicity (CMC). Both ADCC and CMC have been implicated in the killing of Pgp-positive cells by intact anti-Pgp mAb including MRK16 and MRK17 (Tsuruo et al 13 and Iwahashi et al 14 ) . For efficient tumor cell killing, the diabody has to bind and crosslink both the target and the effector T cells simultaneously and to trigger the subsequent activation of the T cells. This only occurs when there are sufficient numbers of both the diabody molecules and the effector cells present within the proximal vicinity of the target cells. Here, we demonstrated that the anti-Pgp Â anti-CD3 diabody lysed potently the Pgpoverexpressing K562/A02 and KBv 200 cells but was much less cytotoxic to K562 and KB cells that express only basal level of Pgp. Further, the diabody efficiently regressed the established Pgp-overexpressing xenografts that do not respond to chemotherapy (Figure 5a and c), but had no effects on the chemosensitive K562 and KB tumors (Figure 5b and d) . Both the K562/A02 and KBv 200 xenografts regained their growth after the termination of the treatment, combined with the observation that the xengrafted KBv 200 cells retained their original level of Pgp expression (Figure 7 ), suggesting that a more frequent and longer dosing schedule is necessary, and more importantly, may lead to sustained tumor inhibition and/or cure. It is also worth noting that, in contrast to the significant systemic toxicity associated with the doxorubicin therapy, the diabody did not cause any overt side effects in the treated mice. Taken together, these observations provide strong support that the antiPgp Â anti-CD3 diabody may represent a safe and efficacious therapeutic agent for the treatment of Pgp-overexpressing MDR cancers in human.
The full-size bispecific IgG antibodies may possess some advantages over smaller BsAb fragments for certain clinical applications by providing the Fc region that not only confers long serum half-life but also supports secondary immune functions, such as ADCC and CMC. [36] [37] [38] The ADCC and CMC activity can be, however, paradoxically both beneficial and detrimental to intended human therapy, depending on the context of the therapeutic intervention. On the other hand, small BsAb fragments, for example, diabody, may prove to be better choice over the intact IgG for other in vivo applications owing to its better tissue penetration and faster clearance from the circulation. Other benefits associated with the use of a diabody include easy production in bacteria at much low cost and less immunogenic in human therapy due to the lack of the Fc domain. , also see Figure 6 ), and stained with PHMA02 for Pgp expression. The cells, including KBv 200 from in vitro culture (a) or from xenografts (b), and KB from in vitro culture (c) or from xenografts (d), were first incubated with PHMA02 (50 mg/ml) at 41C for 1 h, followed by incubation with a FITC-labeled rabbit anti-mouse antibody. The cells were analyzed using a FACS flow cytometer. Control (PBS): dotted line; PHMA02, solid line.
